Michel Goldman

As the problem of COVID-19 vaccines supplies so potently illustrates, it is time to rethink the EU’s pandemic preparedness strategy. More support is needed for late stage clinical development and large scale manufacturing

The European Commission’s work to secure access to potential COVID-19 vaccines is welcome, but other therapies are needed to end the pandemic and negotiations with European manufacturers of anti-viral antibodies should not be further delayed

While providing a good framework, more work is needed to address five priorities for ensuring the successful lifting of lockdown measures.

After decades of research – much of it funded by the public - gene therapy is a reality. Now high costs are blocking patient access. Prices should be constrained